| Colorectal Cancer Treatments and Studies | Lifetime | 17 | US 9 | 99.89 |
| Cancer Treatment and Pharmacology | Lifetime | 34 | US 20 | 99.86 |
| Lung Cancer Treatments and Mutations | Lifetime | 75 | US 44 | 99.76 |
| Economic and Financial Impacts of Cancer | Lifetime | 20 | US 15 | 99.52 |
| Cancer Genomics and Diagnostics | Lifetime | 120 | US 80 | 99.71 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 119 | US 70 | 99.70 |
| Biomedical Ethics and Regulation | Lifetime | 17 | US 12 | 98.48 |
| Gastric Cancer Management and Outcomes | Lifetime | 199 | US 72 | 99.44 |
| Colorectal and Anal Carcinomas | Lifetime | 83 | US 46 | 99.16 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 333 | US 162 | 99.05 |
| Chemotherapy-related skin toxicity | Lifetime | 30 | US 17 | 98.36 |
| Cancer therapeutics and mechanisms | Lifetime | 192 | US 115 | 98.84 |
| Neutropenia and Cancer Infections | Lifetime | 135 | US 69 | 98.58 |
| Lung Cancer Research Studies | Lifetime | 328 | US 153 | 98.70 |
| Statistical Methods in Clinical Trials | Lifetime | 102 | US 53 | 98.12 |
| Advanced Breast Cancer Therapies | Lifetime | 142 | US 70 | 98.73 |
| Multiple Myeloma Research and Treatments | Lifetime | 282 | US 140 | 98.29 |
| HER2/EGFR in Cancer Research | Lifetime | 342 | US 160 | 98.52 |
| Ethics in Clinical Research | Lifetime | 130 | US 80 | 97.02 |
| Genetic factors in colorectal cancer | Lifetime | 497 | US 230 | 98.25 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 761 | US 352 | 98.13 |
| CAR-T cell therapy research | Lifetime | 751 | US 436 | 98.02 |
| Breast Cancer Treatment Studies | Lifetime | 825 | US 369 | 97.72 |
| Protein Degradation and Inhibitors | Lifetime | 466 | US 241 | 96.60 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 639 | US 285 | 97.26 |
| Metastasis and carcinoma case studies | Lifetime | 872 | US 126 | 94.86 |
| PARP inhibition in cancer therapy | Lifetime | 924 | US 388 | 91.21 |
| Biosimilars and Bioanalytical Methods | Lifetime | 954 | US 357 | 88.80 |
| Advances in Oncology and Radiotherapy | Lifetime | 990 | US 472 | 86.99 |
| Science, Research, and Medicine | Lifetime | 193 | US 94 | 88.07 |
| Cancer Genomics and Diagnostics | 2021-2025 | 40 | US 19 | 99.57 |
| Biomedical Ethics and Regulation | 2021-2025 | 5 | US 3 | 98.28 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 112 | US 33 | 98.43 |
| Statistical Methods in Clinical Trials | 2021-2025 | 16 | US 8 | 97.47 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 170 | US 64 | 98.86 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 60 | US 34 | 97.34 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 968 | US 348 | 96.27 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 484 | US 156 | 94.25 |
| Ethics in Clinical Research | 2021-2025 | 253 | US 106 | 87.98 |
| Cancer Treatment and Pharmacology | 2021-2025 | 865 | US 284 | 84.97 |
| Science, Research, and Medicine | 2021-2025 | 64 | US 27 | 73.67 |
